

User agreement for Antibody facility

1. Our standard procedure involves the use of purified protein (provided by the user, 1 mg in PBS) to select single-chain fragment variable antibodies against a given antigen.
2. If the screening needs to be performed against a peptide, it must be a minimum of 30-40 amino acids in length.
3. Users need to provide evidence of QC: SDS-PAGE Coomassie-stained gel with the protein of interest, showing a single, prominent band at the expected molecular weight.
4. Internal QC is performed to check the protein purity and concentration.
5. Users must provide an introduction to their project, clear objectives, and any special requirements regarding the desired epitope. Based on user objectives, deselection protocols will be planned.
6. By the end of the selection process, every selected antibody clone will be checked by ELISA against the antigen. The entire selection procedure takes approximately 10 weeks.
7. The clone is provided to end users after confirmation with colony PCR and sequencing. Antibody purification and final validation must be undertaken by research teams due to the facility's limited capacity.
8. You will nominate a person to serve as our point of contact regarding your project.
9. If you request us to repeat your project, you will be required to cover any additional costs associated with the repeated work.
10. You agree to acknowledge the use of our facility in publications or presentations, in accordance with ICR [values](#) and common [guidelines](#).
11. You can acknowledge us by citing the following DOI <https://doi.org/10.5281/zenodo.14748209>

12. The antibodies developed by the facility are restricted to fundamental research use only. Any commercial development is subject to restrictions and must be discussed with the Institute of Cancer Research.
13. For any antibody inquiries or other questions, contact: AntibodyEnquiries@icr.ac.uk or divya.duscharla@icr.ac.uk